Key Highlights

  • On November 11, 2026, enGene (NASDAQ:ENGN) announced it will start a Biologics License Application for detalimogene by year-end, backed by fresh results from pivotal Cohort 1 of the LEGEND trial.
  • In 120 evaluable patients with BCG-unresponsive non-muscle invasive bladder cancer, 56% reached a complete response at any time, compared with 54% in the earlier update.
  • Complete response at the 12-month landmark improved to 24% from 13%, while the estimated proportion of responders still responding at 12 months moved to 43% from 25%.
  • Treatment-related adverse events affected 59% of patients, largely Grade 1 or 2, and none were Grade 4 or 5.

Details of the Updated Results

enGene (NASDAQ:ENGN) based its LEGEND update on an October 29, 2026 data cutoff, with 120 of the 125 enrolled patients evaluable for efficacy. Detalimogene is a non-viral gene therapy placed straight into the bladder, intended for patients whose disease no longer responds to BCG, the standard immunotherapy, and who would otherwise frequently be facing bladder removal. A complete response at any time was seen in 56%. On durability, the median duration of response grew to 10.1 months from 8.6, and median follow-up among responders is now 12.0 months. Among evaluable patients, 97% stayed free of progression to muscle-invasive disease and 86% avoided cystectomy, a figure that reached 96% among responders. Safety looked mild, with Grade 3 treatment-related events in 4% of patients and serious treatment-related events in 2%. No Grade 4 or 5 treatment-related event occurred, and side effects could generally be handled without halting treatment.

Why the Submission Timeline Is Important

A rolling submission is expected to begin by the end of 2026 and finish in the first half of 2027, with approval possible during 2027. Because the product is non-viral, it is easier to manufacture than viral gene therapies and can be administered in a urology office with no special handling, which may encourage uptake among community urologists, who care for most bladder cancer patients. Competition is real: several therapies for BCG-unresponsive disease have been approved or are near approval in recent years, so detalimogene would arrive in a crowded field. Its case will lean on convenience, tolerability and sparing patients a cystectomy, a major surgery that alters quality of life. Another update is planned for mid-2027 on a cohort that uses a surfactant bladder rinse meant to improve uptake of the therapy, and those findings might raise response rates further and back later label updates. Canadian investors can reach this US-listed name through a Canadian brokerage account.

Key Risks

Durability is the open question. The 24% complete response rate at 12 months sits well below the 56% any-time figure, and both regulators and physicians will measure it against competitors that have shown higher sustained responses. The single-arm design is typical for this setting, yet it leaves cross-trial comparisons open to debate. Being clinical-stage, enGene (NASDAQ:ENGN) must find financing for a launch, and costs will climb as a commercial team is assembled. Market Participants should follow completion of the filing, longer follow-up and the pricing set by other bladder cancer treatments. Scaling up Manufacturing and supplying community practices quickly after approval will be tested too. A tie-up with a larger oncology company could lighten both the funding and commercial load.

Where Things Stand

enGene reported a 56% complete response rate and better durability for detalimogene in BCG-unresponsive bladder cancer, alongside a mild safety profile, and aims to begin its BLA by year-end 2026. Approval may follow in 2027. The 24% complete response at 12 months is the key benchmark against rival therapies, and longer follow-up will shape positioning. Near-term attention stays on delivering the rolling submission.